Abstract 1541
Background
Metastatic Leydig cells tumours (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed LDLR-TERT gene fusion upon routine genetic profiling for detection of therapeutic targets, which was then followed by an investigation into a cohort of additional LCT.
Methods
20 LCT (7 metastatic and 13 primary tumours) from 3 participating institutions (Caris Life Sciences, Phoenix, USA; Clinical Hospital Center, Zagreb, Croatia and Biopticka Laborator, Plzen, Czech Republic) were analyzed using massively parallel DNA and RNA sequencing (NGS) approach. Immunohistochemistry (IHC) was used for detection of selected protein biomarkers.
Results
TERT gene fusions were detected only in metastatic Leydig cell tumours, in three of 5 successfully analyzed cases (RMST:TERT, LDLR:TERT and B4GALT5:TERT, respectively). The case with B4GALT5:TERT fusion also showed amplifications (>6 copies) of TOP1 and CCND3 genes. TP53 mutation (M246I) was detected in one metastatic tumour without TERT fusion. No gene fusions were found in any primary tumours (0/8 successfully analyzed). 3/6 primary tumours showed multiple gene amplifications, without a consistent pattern. At the protein level (IHC) 5/7 metastatic and 6/7 primary tumours over-expressed TOP1. Full length androgen receptor (AR) was overexpressed in 7/8 primary tumours (without detectable ARv7 mRNA or ARv7 protein), but only in 1 of 5 metastatic LCT. No tumours exhibited high tumour mutational burden, microsatellite instability nor expressed PD-L1 in tumour cells.
Conclusions
Our study for the first time identified TERT gene fusions as a main/sole detected genetic alteration and a potential therapeutic target in malignant, metastatic Leydig cell tumours. Additional biomarkers (TOP1 amplification and over-expression) may help guide decisions on chemotherapy for selected individual patients. Androgen receptor blockade may be considered in AR overexpressing tumours without evidence of ARv7 presence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Caris Life Sciences.
Funding
Caris Life Sciences.
Disclosure
Z. Gatalica: Leadership role: Caris Life Sciences. J. Xiu: Leadership role, employment: Caris Life Sciences. J. Swensen: Leadership role, employment: Caris Life Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract